Announcements Trials

Browse Landscape

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 295 Carcinoma, Non-Small-Cell Lung 160 Lung Neoplasms 89 Breast Neoplasms 84 Urinary Bladder Neoplasms 83 Cholangiocarcinoma 58 Neoplasms 53 Neoplasm Metastasis 51 Ovarian Neoplasms 45 Biliary Tract Neoplasms 45 Lymphoma, Large B-Cell, Diffuse 32 Lymphoma 30 Sarcoma 29 Hodgkin Disease 28 Recurrence 26 Nasopharyngeal Carcinoma 26 Gallbladder Neoplasms 26 Carcinoma, Transitional Cell 26 Adenocarcinoma 22 Triple Negative Breast Neoplasms 20 Fallopian Tube Neoplasms 20 Bile Duct Neoplasms 20 Adenocarcinoma of Lung 20 Carcinoma, Renal Cell 17 Carcinoma, Ovarian Epithelial 16 Urethral Neoplasms 15 Lymphoma, Non-Hodgkin 15 Colorectal Neoplasms 14 Leiomyosarcoma 13 Kidney Neoplasms 13

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Gemcitabine × Clear all

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡